鹭燕医药
(002788)
| 流通市值：42.39亿 | | | 总市值：43.13亿 |
| 流通股本：3.82亿 | | | 总股本：3.89亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 10,582,518,010.94 | 5,351,016,756.02 | 21,246,784,960.41 | 15,855,458,775.65 |
| 营业收入 | 10,582,518,010.94 | 5,351,016,756.02 | 21,246,784,960.41 | 15,855,458,775.65 |
| 二、营业总成本 | 10,388,209,566.95 | 5,255,140,222.71 | 20,837,598,561.52 | 15,546,321,924.06 |
| 营业成本 | 9,858,613,408.97 | 4,991,856,600.74 | 19,743,286,782.65 | 14,752,491,090.99 |
| 税金及附加 | 28,302,104.96 | 13,510,477.83 | 54,312,136.86 | 39,115,729.38 |
| 销售费用 | 255,211,145.96 | 123,457,828.15 | 506,944,697.08 | 361,412,296.69 |
| 管理费用 | 157,486,616.05 | 82,453,354.21 | 342,391,043.62 | 250,031,602.1 |
| 研发费用 | 3,764,920.06 | 1,836,509.38 | 6,522,623.96 | 4,271,769.2 |
| 财务费用 | 84,831,370.95 | 42,025,452.4 | 184,141,277.35 | 138,999,435.7 |
| 其中:利息费用 | 80,232,276.96 | 39,440,140.3 | 178,355,014.99 | 135,064,983.86 |
| 其中:利息收入 | 1,092,624.19 | 462,062.67 | 2,661,933.81 | 2,241,256 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -11,590,942.18 | -9,633,727.32 | -14,334,376.29 | -10,884,871.77 |
| 资产处置收益 | -481,570.17 | -577,625.15 | 264,930.44 | 121,974.87 |
| 资产减值损失(新) | -1,055,712 | -152,809.75 | -6,079,575.95 | -1,940,275.19 |
| 信用减值损失(新) | 2,290,516.4 | 1,966,914.89 | -14,132,074.62 | -9,317,325.88 |
| 其他收益 | 4,246,216.72 | 2,872,698.95 | 3,971,955.29 | 2,645,993.37 |
| 四、营业利润 | 187,716,952.76 | 90,351,984.93 | 378,877,257.76 | 289,762,346.99 |
| 加:营业外收入 | 2,897,635.81 | 239,968.14 | 7,997,314.15 | 2,625,479.54 |
| 减:营业外支出 | 1,633,737.85 | 400,259.8 | 10,647,564.98 | 4,131,598.84 |
| 五、利润总额 | 188,980,850.72 | 90,191,693.27 | 376,227,006.93 | 288,256,227.69 |
| 减:所得税费用 | 49,166,100.37 | 24,149,653.94 | 97,245,631.55 | 69,793,093.78 |
| 六、净利润 | 139,814,750.35 | 66,042,039.33 | 278,981,375.38 | 218,463,133.91 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 139,814,750.35 | 66,042,039.33 | 278,981,375.38 | 218,463,133.91 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 143,007,304.14 | 67,936,460.02 | 280,883,792.05 | 219,666,531.25 |
| 少数股东损益 | -3,192,553.79 | -1,894,420.69 | -1,902,416.67 | -1,203,397.34 |
| 扣除非经常损益后的净利润 | 138,311,733.68 | 66,633,844.86 | 282,354,979.15 | 220,139,995.75 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.37 | 0.17 | 0.72 | 0.57 |
| 八、其他综合收益 | -717,821.01 | -423,243.83 | -420,906.77 | -202,411.95 |
| 归属于母公司股东的其他综合收益 | -717,821.01 | -423,243.83 | -420,906.77 | -202,411.95 |
| 九、综合收益总额 | 139,096,929.34 | 65,618,795.5 | 278,560,468.61 | 218,260,721.96 |
| 归属于母公司股东的综合收益总额 | 142,289,483.13 | 67,513,216.19 | 280,462,885.28 | 219,464,119.3 |
| 归属于少数股东的综合收益总额 | -3,192,553.79 | -1,894,420.69 | -1,902,416.67 | -1,203,397.34 |
| 公告日期 | 2026-08-18 | 2026-04-21 | 2026-04-21 | 2025-10-27 |
| 审计意见(境内) | | | 标准无保留意见 | |